Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
Type II diabetes costs the NHS £8.8 billion a year.
Read More
Tag: Januvia
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Read More
US green light for Pfizer/Merck diabetes therapies
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Read More
FDA rejects CV outcomes claim for Merck diabetes drugs
The US Food and Drug Administration has dealt Merck & Co a blow in turning down its request to have cardiovascular outcomes data added to the labels of its diabetes drugs Januvia and Janumet.
Read More
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
